FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * GADICKE ANSBERT 2. Issuer Name and Ticker or Trading Symbol iTeos Therapeutics, Inc. [ ITOS ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O MPM CAPITAL, 450 KENDALL STREET
3. Date of Earliest Transaction (MM/DD/YYYY)
9/7/2021
(Street)
CAMBRIDGE, MA 02142
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/7/2021    S(1)    50996 (2)(3) D $29.18 (4) 5953372  I  See Footnote (5)
Common Stock  9/7/2021    J(6)    31340 (7) D $0.00  5922032  I  See Footnote (8)
Common Stock  9/8/2021    S(1)    18663 (9) D $28.61 (10) 5903369  I  See Footnote (11)
Common Stock  9/8/2021    S(1)    1573 (12) D $29.10 (13) 5901796  I  See Footnote (14)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
(2)  The shares were sold as follows: 18,156 by MPM BioVentures 2014, L.P. ("BV 2014"), 625 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 11,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 226 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 20,522 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.
(3)  BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(4)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.89 to $29.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(5)  The shares are held as follows: 2,050,714 by BV 2014, 128,561 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,585 by AM BV2014, 1,295,187 by BV 2018, 64,705 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 25,561 by AM BV2018 and 2,318,059 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(6)  Represents a pro rata in-kind distribution from BV 2014(B) and BV 2018(B) to its respectve limited partners for no consideration.
(7)  The shares were distributed as follows: 20,848 shares by BV 2014(B) and 10,492 shares by BV 2018(B).
(8)  The shares are held as follows: 2,050,714 by BV 2014, 107,713 by BV 2014(B), 70,585 by AM BV2014, 1,295,187 by BV 2018, 54,213 by BV 2018(B), 25,561 by AM BV2018 and 2,318,059 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(9)  The shares were sold as follows: 6,644 by BV 2014, 229 by AM BV2014, 4,196 by BV 2018, 83 by AM BV2018 and 7,511 by UBS Oncology.
(10)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(11)  The shares are held as follows: 2,044,070 by BV 2014, 107,713 by BV 2014(B), 70,356 by AM BV2014, 1,290,991 by BV 2018, 54,213 by BV 2018(B), 25,478 by AM BV2018 and 2,310,548 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(12)  The shares were sold as follows: 560 by BV 2014, 19 by AM BV2014, 354 by BV 2018, 7 by AM BV2018 and 633 by UBS Oncology.
(13)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.04 to $29.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(14)  The shares are held as follows: 2,043,510 by BV 2014, 107,713 by BV 2014(B), 70,337 by AM BV2014, 1,290,637 by BV 2018, 54,213 by BV 2018(B), 25,471 by AM BV2018 and 2,309,915 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
GADICKE ANSBERT
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE, MA 02142

X

UBS Oncology Impact Fund L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE, MA 02142

X

BioImpact Capital LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE, MA 02142

X

Oncology Impact Fund (Cayman) Management L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE, MA 02142

X


Signatures
/s/ Ansbert Gadicke 9/8/2021
**Signature of Reporting Person Date
/s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC, the general partner of Oncology Impact Fund (Cayman) Management L.P., the general partner of UBS Oncology Impact Fund L.P 9/8/2021
**Signature of Reporting Person Date
/s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC 9/8/2021
**Signature of Reporting Person Date
/s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC, the general partner of Oncology Impact Fund (Cayman) Management L.P. 9/8/2021
**Signature of Reporting Person Date
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more iTeos Therapeutics Charts.
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more iTeos Therapeutics Charts.